Primary Hypertension
Özet
Primary hypertension is a prevalent global chronic disease significantly associated with cardiovascular complications, stroke, and renal failure. Despite available therapies, blood pressure control remains suboptimal due to poor compliance, lack of lifestyle modification, and isolated systolic hypertension in elderly populations. While major international guidelines (ISH, ESC/ESH, and ACC/AHA) align closely on standard diagnostic thresholds, the 2017 ACC/AHA criteria adopt lower values for defining hypertension. Accurate diagnosis relies heavily on standardized measurement techniques, home monitoring, and Ambulatory Blood Pressure Monitorization (ABPM), the latter being particularly crucial for identifying white-coat or masked hypertension and managing nocturnal non-dipping patterns. Pathophysiologically, primary hypertension involves complex, multi-factorial mechanisms including abnormal pressure-natriuresis, sympathetic nervous system hyperactivity, renin-angiotensin-aldosterone system alterations, oxidative stress, and genetic variations affecting renal sodium transport. Pharmacological intervention requires a highly tailored, individualized approach. Monotherapy involving thiazide diuretics, calcium channel blockers, or ACE inhibitors/ARBs is effective for mild cases, whereas combination therapy is recommended when blood pressure significantly exceeds target levels, as evidenced by major clinical trials like ALLHAT and ACCOMPLISH. Ultimately, effective hypertension management requires a strict combination of patient adherence, continuous clinical monitoring, and comprehensive lifestyle changes to prevent long-term target organ damage.
Referanslar
Definition of hypertensionandpressuregoalsduringtreatment (ESC-ESH Guidelines 2018) Dr. IhabRamzy , FESC E-Journal of CardiologyPractice-volume 17
CurrentDiagnosisandTreatmentNephrologyandHypertensionChapter 40 H. Yamout, G.L.Bakris
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al.InternationalSociety of Hypertension Global HypertensionPracticeGuidelines.Hypertension 2020;75:1334–57. 2020.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelinesforthemanagement of arterialhypertension. EurHeart J 2018; 39:3021.https://doi.org/10.1093/eurheartj/ehy339.
Verdecciha P, Reboldi G, AngeliF.Eur J InternMed. 2020The 2020 International Society of Hypertension global hypertensionpracticeguidelines -keymessagesandclinicalconsiderations. Dec;82:1-6. doi: 10.1016/j.ejim.2020.09.001. Epub 2020 Sep 22.PMID: 32972800
Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA GuidelineforthePrevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of theAmericanCollege of Cardiology/AmericanHeartAssociationTask Force on ClinicalPracticeGuidelines. Hypertension 2018; 71:e13.
Arıcı M, Birdane A, Güler K, Yıldız BO, Altun B, Ertürk Ş ve ark. Türk hipertansiyon uzlaşı raporu. Türk KardiyolDern Arş 2015;43:402−9
S.Aydoğdu, K.Güler, F.Bayram, B.Altun, Ü.Derici, A.Abacı, T.Tükek, T.Sabuncu, M.Arıcı, Y.Erdem, B.Özin, İ.Şahin, Ş.Ertürk, A.Bitigen, L.Tokgözoğlu Türk Hipertansiyon Uzlaşı Raporu 2019 (2019 Turkish Hypertension Consensus Report)Turk Kardiyol Dern Ars2019;47(6):535-546 doi:0.5543/tkda.2019.62565
Cohen JB, Lotito MJ, Trivedi UK, et al. CardiovascularEventsandMortality in White CoatHypertension: A SystematicReviewand Meta-analysis. AnnInternMed 2019; 170:853.
Carey RM, CalhounDA,Bakris GL, et al. ResistantHypertension: Detection, Evaluation, and Management: A Scientific Statement FromtheAmericanHeartAssociation. Hypertension 2018; 72:e53.
Pierdomenico SD, Pierdomenico AM, Coccina F, et al. Prognostic Value of MaskedUncontrolledHypertension. Hypertension 2018; 72:862
Rahman M, Wang X, Bundy JD, et al. PrognosticSignificance of Ambulatory BP Monitoring in CKD: A Report fromtheChronicRenalInsufficiencyCohort (CRIC) Study. J AmSocNephrol 2020; 31:2609.
Piper MA, Evans CV, Burda BU, et al. Diagnosticandpredictiveaccuracy of bloodpressurescreeningmethodswithconsideration of rescreeningintervals: a systematicreviewforthe U.S. Preventive Services Task Force. AnnInternMed 2015; 162:192.
Salles GF, Leite NC, Pereira BB, et al. Prognosticimpact of clinicandambulatorybloodpressurecomponents in high-risk type 2 diabeticpatients: the Rio de Janeiro Type 2 DiabetesCohortStudy. J Hypertens 2013; 31:2176
Staessen JA, Bieniaszewski L, O'Brien E, et al. Nocturnalbloodpressurefall on ambulatorymonitoring in a largeinternationaldatabase. The "Ad Hoc' WorkingGroup. Hypertension 1997; 29:30.
Andersen MJ, Khawandi W, Agarwal R. Home bloodpressuremonitoring in CKD. Am J KidneyDis 2005; 45:994.
Fan HQ, Li Y, Thijs L, et al. Prognosticvalue of isolatednocturnalhypertension on ambulatorymeasurement in 8711 individualsfrom 10 populations. J Hypertens 2010; 28:2036.
Ingelsson E, Björklund-Bodegård K, Lind L, et al. Diurnalbloodpressurepatternand risk of congestiveheartfailure.JAMA 2006; 295:2859.
Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaireddiurnalbloodpressurevariationwith a subsequentdecline in glomerularfiltration rate. ArchInternMed 2006; 166:846.
DI Feig, B Soletsky, RJ Johnson: Effect of allopurinol on bloodpressure of adolescentswithnewlydiagnosedessentialhypertension: a randomizedtrial. JAMA. 300:924-932 2008 PMID 18728266
MP Blaustein, FH Leenen, Chen L, et al.: How NaClraisesbloodpressure: a newparadigmforthepathogenesis of salt-dependenthypertension. Am J PhysiolHeartCircPhysiol. 302:H1031-H1049 2012 PMID 22058154
S Julius: The evidencefor a pathophysiologicsignificance of thesympatheticoveractivity in hypertension. ClinExpHypertens. 18:305-321 1996 PMID 8743023
RP Lifton: Geneticdissection of humanbloodpressurevariation: commonpathwaysfromrarephenotypes. HarveyLect. 100:71-101 2004 PMID 16970175
BM Brenner, DL Garcia, S Anderson: Glomeruliandbloodpressure. Less of one, moretheother?.Am J Hypertens. 1:335-347 1988 PMID 3063284
DJ Barker, C Osmond, J Golding, et al.: Growth in utero, bloodpressure in childhoodandadult life, andmortalityfromcardiovasculardisease. BMJ. 298:564-567 1989 PMID2495113
B Rodriguez-Iturbe, H Pons, RJ Johnson: The immunebasis of hypertension. PhysiolRev. 97:1127-1164 2017 PMID 28566539
A Kirabo, V Fontana, AP de Faria, et al.: DC isoketal-modifiedproteinsactivate T cellsandpromotehypertension. J ClinInvest. 124:4642-4656 2014 PMID 25244096
F Forette, ML Seux, JA Staessen, et al.: Prevention of dementia in randomiseddouble-blindplacebo-controlledSystolicHypertension in Europe (Syst-Eur) trial. Lancet. 352:1347-1351 1998 PMID9802273
Franklin SS, Larson MG, Khan SA, et al. Doestherelation of bloodpressuretocoronaryheartdisease risk changewithaging? The FraminghamHeartStudy. Circulation 2001; 103:1245.
Taylor BC, Wilt TJ, Welch HG. Impact of diastolicandsystolicbloodpressure on mortality: implicationsforthedefinition of "normal". J Gen InternMed 2011; 26:685.
S MacMahon, R Peto, J Cutler, et al.: Blood pressure, stroke, andcoronaryheartdisease. Part 1, Prolongeddifferences in bloodpressure: prospectiveobservationalstudiescorrectedfortheregressiondilutionbias. Lancet. 335:765-774 1990 PMID1969518
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovasculareventswith an antihypertensiveregimen of amlodipineaddingperindopril as requiredversusatenololaddingbendroflumethiazide as required, in theAnglo-ScandinavianCardiacOutcomes Trial-Blood PressureLoweringArm (ASCOT-BPLA): a multicentrerandomisedcontrolledtrial. Lancet 2005; 366:895.
Fox KM, EURopeantrial On reduction of cardiaceventswithPerindopril in stablecoronaryArterydiseaseInvestigators. Efficacy of perindopril in reduction of cardiovasculareventsamongpatientswithstablecoronaryarterydisease: randomised, double-blind, placebo-controlled, multicentretrial (the EUROPA study). Lancet 2003; 362:782.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensivepatients at highcardiovascular risk treatedwithregimensbased on valsartanoramlodipine: the VALUE randomisedtrial. Lancet 2004; 363:2022.,
Weber MA, Julius S, Kjeldsen SE, et al. Blood pressuredependentandindependenteffects of antihypertensivetreatment on clinicalevents in the VALUE Trial. Lancet 2004; 363:2049.
ALLHAT OfficersandCoordinatorsforthe ALLHAT CollaborativeResearchGroup. The AntihypertensiveandLipid-LoweringTreatmenttoPreventHeart Attack Trial. Majoroutcomes in high-risk hypertensivepatientsrandomizedtoangiotensin-convertingenzymeinhibitororcalciumchannelblockervsdiuretic: The AntihypertensiveandLipid-LoweringTreatmenttoPreventHeart Attack Trial (ALLHAT). JAMA 2002; 288:2981.
SR Group, JT Wright Jr, JD Williamson, et al.: A Randomized Trial of Intensiveversus Standard Blood-Pressure Control. N Engl J Med. 373:2103-2116 2015 PMID 26551272
Thomopoulos C, Parati G, Zanchetti A. Effects of bloodpressure-loweringtreatment on cardiovascularoutcomesandmortality: 14 -effects of differentclasses of antihypertensivedrugs in olderandyoungerpatients: overviewand meta-analysis. J Hypertens 2018; 36:1637.
T Krause, K Lovibond, M Caulfield, et al.: Management of hypertension: summary of NICE guidance. Guideline Development Group. BMJ.43:d4891 2011 Full resources; available at: http://www.nice.org.uk/CG034guidanceandhttp://guidance.nice.org.uk/CG127
D Ettehad, CA Emdin, A Kiran, et al.: Blood pressureloweringforprevention of cardiovasculardiseaseanddeath: a systematicreviewand meta-analysis. Lancet. 387 (10022):957-967 2016 26724178,
Weber MA, Schiffrin EL, White WB, et al. Clinicalpracticeguidelinesforthemanagement of hypertension in thecommunity a statementbytheAmericanSociety of Hypertensionandthe International Society of Hypertension. J Hypertens 2014; 32:3.
ESH/ESC Task Force forthe Management of ArterialHypertension. 2013 Practiceguidelinesforthemanagement of arterialhypertension of theEuropeanSociety of Hypertension (ESH) andtheEuropeanSociety of Cardiology (ESC): ESH/ESC Task Force forthe Management of ArterialHypertension. J Hypertens 2013; 31:1925.
Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overviewand meta-analysis of randomizedoutcometrials. J Hypertens 2020; 38:1669.
JM Mason, HO Dickinson, DJ Nicolson, et al.: The diabetogenicpotential of thiazide-typediureticand beta-blockercombinations in patientswithhypertension. J Hypertens. 23:1777-1781 2005 16148594
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelinesforthemanagement of arterialhypertension: theTask Force forthemanagement of arterialhypertension of theEuropeanSociety of Hypertension (ESH) and of theEuropeanSociety of Cardiology (ESC). J Hypertens 2013; 31:1281.
Law MR, Morris JK, Wald NJ. Use of bloodpressureloweringdrugs in theprevention of cardiovasculardisease: meta-analysis of 147 randomisedtrials in thecontext of expectationsfromprospectiveepidemiologicalstudies. BMJ 2009; 338:b1665.
Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensivetreatmentbycrossoverrotation of fourmajorclasses. Lancet 1999; 353:2008.
Eguchi K, Kario K, Hoshide Y, et al. Comparison of valsartanandamlodipine on ambulatoryandmorningbloodpressure in hypertensivepatients. Am J Hypertens 2004; 17:112.
Weber MA, Jamerson K, Bakris GL, et al. Effects of body size andhypertensiontreatments on cardiovasculareventrates: subanalysis of the ACCOMPLISH randomisedcontrolledtrial. Lancet 2013; 381:537.
Pickering TG. The use of angiotensinconvertingenzymeinhibitors in combinationwithotherantihypertensiveagents.Am J Hypertens 1991; 4:73S.
Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtimehypertensiontreatmentimprovescardiovascular risk reduction: theHygiaChronotherapy Trial. EurHeart J 2020; 41:4565.
Jamerson K, Weber MA, Bakris GL, et al. Benazeprilplusamlodipineorhydrochlorothiazideforhypertension in high-risk patients. N Engl J Med 2008; 359:2417.
Jamerson KA, Bakris GL, Wun CC, et al. Rationaleanddesign of theavoidingcardiovasculareventsthroughcombinationtherapy in patientslivingwithsystolichypertension (ACCOMPLISH) trial: thefirstrandomizedcontrolledtrialtocomparetheclinicaloutcomeeffects of first-linecombinationtherapies in hypertension. Am J Hypertens 2004; 17:793.
Bakris GL, Sarafidis PA, Weir MR, et al. Renaloutcomeswithdifferentfixed-dosecombinationtherapies in patientswithhypertension at high risk forcardiovascularevents (ACCOMPLISH): a prespecifiedsecondaryanalysis of a randomisedcontrolledtrial. Lancet 2010; 375:1173.
Jamerson KA, Devereux R, Bakris GL, et al. Efficacyandduration of benazeprilplusamlodipineorhydrochlorothiazide on 24-hour ambulatorysystolicbloodpressurecontrol. Hypertension 2011; 57:174.
Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright Jr. JT, et al. PotentialUSPopulationImpact of the 2017 ACC/AHA High Blood PressureGuideline.Circulation 2018;137:109–18
